Title	Overall survival
Number of Patients Screened	35
Number of Patients Enrolled	35
Number of Patients Evaluable for Toxicity	35
Number of Patients Evaluated for Efficacy	35
(Median) Duration Assessments OS	30.8 months, CI: 17.9–not evaluable
Title	PSA‐PFS
Number of Patients Screened	35
Number of Patients Enrolled	35
Number of Patients Evaluable for Toxicity	35
Number of Patients Evaluated for Efficacy	35
Evaluation Method	Prostate Cancer Working Group 2 (PCWG2)
(Median) Duration Assessments PFS	8.9 months, CI: 4.73–21.4
Title	Radiographic PFS
Number of Patients Screened	35
Number of Patients Enrolled	35
Number of Patients Evaluable for Toxicity	35
Number of Patients Evaluated for Efficacy	35
Evaluation Method	Progressive disease on imaging
(Median) Duration Assessments PFS	11.5 months, CI: 9.2–29
Title	Radiographic objective response rate
Number of Patients Screened	35
Number of Patients Enrolled	35
Number of Patients Evaluable for Toxicity	35
Number of Patients Evaluated for Efficacy	35
Evaluation Method	Radiographic Response
Response Assessment CR	n = 0 (0%)
Response Assessment PR	n = 3 (9%)
Response Assessment SD	n = 28 (80%)
Response Assessment PD	n = 4 (11%)
Title	Post hoc: PSA‐PFS2
Number of Patients Screened	35
Number of Patients Enrolled	35
Number of Patients Evaluable for Toxicity	35
Number of Patients Evaluated for Efficacy	35
Evaluation Method	PCWG2—time from start of protocol therapy to PSA progression on subsequent therapy
(Median) Duration Assessments PFS	18.7 months, CI: 12.2–42.8
Title	Post hoc: TTNT
Number of Patients Screened	35
Number of Patients Enrolled	35
Number of Patients Evaluable for Toxicity	35
Number of Patients Evaluated for Efficacy	35
Evaluation Method	time to subsequent therapy
(Median) Duration Assessments PFS	15.9 months, CI: 9.7–35.5